—
C+
C+ The full Closelook — membership. Open the C+ overview

Caris Life Sciences, Inc. Common Stock (CAI) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Caris Life Sciences, Inc. Common Stock

CAI in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Caris Life Sciences profiles tumours at the molecular level, sequencing DNA, RNA and whole genomes to guide cancer treatment choices. Its platforms cover tissue and blood based tests, including whole exome and whole genome sequencing, early detection and residual disease monitoring tools. It also runs research services for biopharmaceutical companies using the molecular data it generates. The company is based in Irving, Texas, and trades on a US exchange.
Where it sits in the stack
Caris sits outside our index universe for now; it belongs to the healthcare corner of our coverage, in the biotechnology sleeve rather than the chip or infrastructure sleeves the diary tracks for the AI build-out. Its own use of machine learning sits in diagnostics, applying models to sequencing data rather than supplying compute, tools or capacity to the stack.
Who it is priced against
The diary has not placed it in a peer group yet; the comparison the market often draws is with Guardant Health, another company built around molecular profiling in oncology.
Why Closelook tracks it
Caris does not hold a seat in any Closelook index, and the diary has not built a score for it since coverage only began after its listing. No quotes have run for it in our editions so far.
What the diary watches
The diary watches whether enough trading history builds up for our score and index screens to pick the name up, and whether its early post-listing price swings settle as more quarters of results come through.

Caris Life Sciences, Inc. Common Stock (CAI) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 59/100 composite (momentum 73, quality 60, valuation 31) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CAI, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against CAI on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 113,000 USD in FY2025

Dividends and capital return

What CAI pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 113,000 USD 0.0% of today's market value
  • Share count +13.8% in FY2025 70 m USD of stock-based compensation in the year
  • Capital returned 113,000 USD · 0% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in US: +1.8% week · −4.1% month · +13.2% quarter · +8.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Caris Life Sciences, Inc. Common Stock (CAI)?

Caris Life Sciences, Inc. Common Stock trades as CAI on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is CAI in a Closelook index?

Not currently — Caris Life Sciences, Inc. Common Stock is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Caris Life Sciences, Inc. Common Stock's Closelook composite score?

59 out of 100, with momentum 73, quality 60 and valuation 31 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does CAI trade against its moving averages?

Uptrend stack intact: Trades +39.1% vs the 50-day and +42.5% vs the 200-day average, 13.2% below the 52-week high and +111.3% off the 52-week low; a golden cross printed 3 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Caris Life Sciences, Inc. Common Stock do?

Caris Life Sciences profiles tumours at the molecular level, sequencing DNA, RNA and whole genomes to guide cancer treatment choices. Its platforms cover tissue and blood based tests, including whole exome and whole genome sequencing, early detection and residual disease monitoring tools. It also runs research services for biopharmaceutical companies using the molecular data it generates. The diary has not placed it in a peer group yet; the comparison the market often draws is with Guardant Health, another company built around molecular profiling in oncology.

Where does Caris Life Sciences, Inc. Common Stock sit in the AI build-out?

Caris sits outside our index universe for now; it belongs to the healthcare corner of our coverage, in the biotechnology sleeve rather than the chip or infrastructure sleeves the diary tracks for the AI build-out. Its own use of machine learning sits in diagnostics, applying models to sequencing data rather than supplying compute, tools or capacity to the stack. Caris does not hold a seat in any Closelook index, and the diary has not built a score for it since coverage only began after its listing. No quotes have run for it in our editions so far.

Does Caris Life Sciences, Inc. Common Stock pay a dividend?

No cash distribution shows in Caris Life Sciences, Inc. Common Stock’s price series over the last three years. In fiscal 2025 the company bought back 113,000 USD of its own shares, 0% of that year’s free cash flow. The share count rose 13.8% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CAI, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.